(Medical Xpress)—Anticoagulants have saved the lives of those at risk for heart attack or stroke. However, because they prevent blood clotting, they can be dangerous to patients who suffer traumatic injuries or who require ...
A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in ...
Aug 28, 2011
1
0
When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.
Dec 14, 2023
0
1
Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45% compared to the traditional drug Waran (warfarin) in the treatment of blood clots in the legs and lungs. All according to a comprehensive ...
Aug 29, 2023
0
0
A cohort study of more than 90,000 older adults diagnosed with atrial fibrillation (Afib) who were treated with anticoagulants found that treatment with amiodarone during apixaban or rivaroxaban use was associated with greater ...
May 22, 2023
0
2
A large-scale comparison of direct oral anticoagulants (blood thinners), commonly prescribed for irregular heartbeats, has identified the drug associated with the lowest risk of bleeding, in a new study led by UCL researchers.
Oct 31, 2022
0
45
A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic embolism and a lower rate ...
Oct 18, 2022
0
4
The oral anticoagulant drug apixaban may offer a safer, more effective alternative to standard home heparin injections for patients taking extended prophylaxis (EP) to prevent blood-clot-related complications after surgery, ...
Sep 12, 2022
0
11
(HealthDay)—For people suffering from clots in their legs, a new study finds that one of two commonly used blood thinners is safer and more effective than the other.
Dec 7, 2021
0
5
(HealthDay)—Compared with placebo, neither aspirin nor apixaban reduces the rate of major adverse cardiovascular or pulmonary outcomes for clinically stable outpatients with symptomatic COVID-19, according to a study published ...
Oct 18, 2021
0
16
